anti-CD19-CAR-T cells
Sponsors
Shanghai GeneChem Co., Ltd., The Children's Hospital of Zhejiang University School of Medicine, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Shanghai First Song Biotechnology Co., LTD
Conditions
ANCA Associated VasculitisAntiphospholipid SyndromeB Cell MalignanciesB-Cell MalignancyCAR-T Cell TherapyInflammatory MyopathyLeukemia, B-CellSjogren's Syndrome
Early Phase 1
Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.
RecruitingNCT06375161
Start: 2023-12-11End: 2039-12-10Target: 12Updated: 2024-04-19
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
Not yet recruitingNCT06420154
Start: 2024-05-27End: 2027-05-27Target: 9Updated: 2024-05-17
Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies
RecruitingNCT06532630
Start: 2023-08-24End: 2026-09-01Target: 9Updated: 2025-02-28
Phase 1
A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
NCT02672501
Start: 2016-01-31End: 2019-12-31Target: 30Updated: 2016-02-03
A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)
NCT03030976
Start: 2017-03-31End: 2018-03-31Target: 5Updated: 2017-02-07
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus
Active, not recruitingNCT06222853
Start: 2024-02-10End: 2026-12-30Updated: 2026-02-04